CTI BioPharma gets on the FDA fast track with its cancer drug

Seattle's CTI BioPharma ($CTIC) picked up the FDA's fast-track designation for pacritinib, a late-stage treatment for blood cancer. The drug, which treats intermediate- and high-risk myelofibrosis, is in the midst of two Phase III trials. With the FDA's designation, CTI's treatment is guaranteed an expedited review once it's submitted, and the company will be able to file its application on a rolling basis as results from its late-stage program come in. More